AR049548A1 - Derivados de aminopiridina y su uso como farmacos - Google Patents
Derivados de aminopiridina y su uso como farmacosInfo
- Publication number
- AR049548A1 AR049548A1 ARP050102169A ARP050102169A AR049548A1 AR 049548 A1 AR049548 A1 AR 049548A1 AR P050102169 A ARP050102169 A AR P050102169A AR P050102169 A ARP050102169 A AR P050102169A AR 049548 A1 AR049548 A1 AR 049548A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- phenyl
- optionally substituted
- independently selected
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/73—Unsubstituted amino or imino radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Pregnancy & Childbirth (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0411891A GB0411891D0 (en) | 2004-05-27 | 2004-05-27 | New aminopyridine derivatives and their use as pharmaceuticals |
| GB0412463A GB0412463D0 (en) | 2004-06-03 | 2004-06-03 | New aminopyridine derivatives and their use as pharmaceuticals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR049548A1 true AR049548A1 (es) | 2006-08-16 |
Family
ID=34970000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050102169A AR049548A1 (es) | 2004-05-27 | 2005-05-26 | Derivados de aminopiridina y su uso como farmacos |
Country Status (21)
| Country | Link |
|---|---|
| EP (1) | EP1758862A1 (ru) |
| JP (1) | JP4198183B2 (ru) |
| AP (1) | AP2006003824A0 (ru) |
| AR (1) | AR049548A1 (ru) |
| AU (1) | AU2005247699A1 (ru) |
| BR (1) | BRPI0511571A (ru) |
| CA (1) | CA2567935C (ru) |
| EA (1) | EA200601982A1 (ru) |
| EC (1) | ECSP067029A (ru) |
| GT (1) | GT200500125A (ru) |
| IL (1) | IL179314A0 (ru) |
| MA (1) | MA28607B1 (ru) |
| MX (1) | MXPA06013786A (ru) |
| NL (1) | NL1029139C2 (ru) |
| NO (1) | NO20065326L (ru) |
| PA (1) | PA8635101A1 (ru) |
| PE (1) | PE20060366A1 (ru) |
| SV (1) | SV2005002129A (ru) |
| TW (1) | TW200609216A (ru) |
| UY (1) | UY28925A1 (ru) |
| WO (1) | WO2005115985A1 (ru) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
| AU2010213192A1 (en) | 2009-02-13 | 2011-08-04 | Bayer Intellectual Property Gmbh | Fused pyrimidines |
| WO2011130194A2 (en) * | 2010-04-12 | 2011-10-20 | Supernus Pharmaceuticals Inc. | Methods for producing viloxazine salts and novel polymorphs thereof |
| US9504949B2 (en) | 2011-06-30 | 2016-11-29 | Donaldson Company, Inc. | Air/oil separator assemblies; components; and methods |
| GB2543296A (en) * | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
| CN114014844B (zh) | 2016-07-20 | 2024-10-01 | 诺华股份有限公司 | 氨基吡啶衍生物及其作为选择性alk-2抑制剂的用途 |
| WO2020210785A1 (en) * | 2019-04-12 | 2020-10-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | D3 receptor agonist compounds; methods of preparation; intermediates thereof; and methods of use thereof |
| WO2021102258A1 (en) | 2019-11-22 | 2021-05-27 | Incyte Corporation | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| CA3187767A1 (en) | 2020-06-16 | 2021-12-23 | Incyte Corporation | Alk2 inhibitors for the treatment of anemia |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5077290A (en) * | 1990-10-11 | 1991-12-31 | Merck & Co., Inc. | Morpholine derivatives compositions and use |
| GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
| WO2004052372A1 (en) * | 2002-12-10 | 2004-06-24 | Pfizer Limited | Morpholine derivatives for use as dopamine agonists in the treatment of i.a. sexual dysfunction |
-
2005
- 2005-05-17 EA EA200601982A patent/EA200601982A1/ru unknown
- 2005-05-17 BR BRPI0511571-0A patent/BRPI0511571A/pt not_active Application Discontinuation
- 2005-05-17 AU AU2005247699A patent/AU2005247699A1/en not_active Abandoned
- 2005-05-17 EP EP05747191A patent/EP1758862A1/en not_active Withdrawn
- 2005-05-17 WO PCT/IB2005/001554 patent/WO2005115985A1/en active Application Filing
- 2005-05-17 JP JP2007514200A patent/JP4198183B2/ja not_active Expired - Fee Related
- 2005-05-17 AP AP2006003824A patent/AP2006003824A0/xx unknown
- 2005-05-17 CA CA002567935A patent/CA2567935C/en not_active Expired - Fee Related
- 2005-05-17 MX MXPA06013786A patent/MXPA06013786A/es not_active Application Discontinuation
- 2005-05-24 GT GT200500125A patent/GT200500125A/es unknown
- 2005-05-25 PE PE2005000583A patent/PE20060366A1/es not_active Application Discontinuation
- 2005-05-26 TW TW094117274A patent/TW200609216A/zh unknown
- 2005-05-26 NL NL1029139A patent/NL1029139C2/nl not_active IP Right Cessation
- 2005-05-26 AR ARP050102169A patent/AR049548A1/es unknown
- 2005-05-26 PA PA20058635101A patent/PA8635101A1/es unknown
- 2005-05-26 UY UY28925A patent/UY28925A1/es not_active Application Discontinuation
- 2005-05-27 SV SV2005002129A patent/SV2005002129A/es not_active Application Discontinuation
-
2006
- 2006-11-15 IL IL179314A patent/IL179314A0/en unknown
- 2006-11-20 NO NO20065326A patent/NO20065326L/no unknown
- 2006-11-27 EC EC2006007029A patent/ECSP067029A/es unknown
- 2006-11-27 MA MA29488A patent/MA28607B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2567935A1 (en) | 2005-12-08 |
| CA2567935C (en) | 2009-10-27 |
| ECSP067029A (es) | 2006-12-29 |
| PE20060366A1 (es) | 2006-05-15 |
| IL179314A0 (en) | 2007-03-08 |
| NL1029139C2 (nl) | 2006-06-19 |
| EA200601982A1 (ru) | 2007-04-27 |
| GT200500125A (es) | 2006-01-10 |
| JP2008500331A (ja) | 2008-01-10 |
| SV2005002129A (es) | 2005-12-13 |
| AU2005247699A1 (en) | 2005-12-08 |
| BRPI0511571A (pt) | 2008-01-02 |
| MXPA06013786A (es) | 2007-01-25 |
| NO20065326L (no) | 2006-12-19 |
| JP4198183B2 (ja) | 2008-12-17 |
| AP2006003824A0 (en) | 2006-12-31 |
| PA8635101A1 (es) | 2006-05-16 |
| MA28607B1 (fr) | 2007-05-02 |
| EP1758862A1 (en) | 2007-03-07 |
| TW200609216A (en) | 2006-03-16 |
| UY28925A1 (es) | 2005-12-30 |
| NL1029139A1 (nl) | 2005-11-30 |
| WO2005115985A1 (en) | 2005-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR049548A1 (es) | Derivados de aminopiridina y su uso como farmacos | |
| PE20181024A1 (es) | Derivados de ciclohexano sustituido con amido | |
| PE20210163A1 (es) | Nuevas piridopirimidinonas sustituidas con bencilamino y derivados como inhibidores de sos1 | |
| ECSP22058816A (es) | Compuestos tric?clicos sustituidos | |
| PE20181298A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| PE20190395A1 (es) | Pirimidin-2-ilamino-1h-pirazoles como inhibidores de lrrk2 para el uso en el tratamiento de trastornos neurodegenerativos | |
| ES2669189T3 (es) | Compuestos de carbazol útiles como inhibidores del bromodominio | |
| ECSP16025201A (es) | Profármacos de amidas de piridona útiles como moduladores de canales de sodio | |
| CO2017000438A2 (es) | Ácidos carboxílicos heterocíclicos como activadores de guanilato ciclasa soluble | |
| PE20200665A1 (es) | Compuestos espirociclicos y sus metodos de preparacion y uso | |
| PE20191784A1 (es) | Compuestos inhibidores de vmat2, composiciones y metodos relativos a los mismos | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| AR046200A1 (es) | Derivados de pirazina y su uso farmaceutico. procesos de preparacion y composiciones farmaceuticas | |
| AR079327A1 (es) | Derivados de 2-amino-5,5-difluor -5,6-dihidro-4h-(1,3) oxazin-4-il) fenil)-amida | |
| AR048289A1 (es) | Eteres de anillos imidazo sulfona sustituidos. | |
| PE20161313A1 (es) | Heteroarilos y usos de estos | |
| PE20161443A1 (es) | Compuestos | |
| PE20191495A1 (es) | Piridonamidas como moduladores de canales de sodio | |
| PE20130149A1 (es) | Derivados de la cromenona con actividad anti-tumoral | |
| ECSP15012804A (es) | Alcoxipirazoles como activadores de guanilato ciclasa soluble | |
| UY35551A (es) | Derivados heteroarilos como inhibidores de aldosterona sintasa | |
| AR055744A1 (es) | Derivados de acido pirimidincarboxilico, su uso para preparar medicamentos y preparacion de dicjhos compuestos | |
| CL2012000516A1 (es) | Compuestos derivados de 3-[4-(4-(fenil/piridin/ pirimidin)- piperazin -1-il)-butil]-2, 3-dihidro-4h-croman-4-ona, moduladores del receptor de dopamina d3; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de un desorden neurologico o psiquiatrico, disfuncion erectil o dependencia a drogas, entre otros. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |